These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 18164223)
21. HFE based re-evaluation of heterozygous hemochromatosis. Moirand R; Guyader D; Mendler MH; Jouanolle AM; Le Gall JY; David V; Brissot P; Deugnier Y Am J Med Genet; 2002 Sep; 111(4):356-61. PubMed ID: 12210292 [TBL] [Abstract][Full Text] [Related]
22. Correlation between genotype and phenotype in hereditary hemochromatosis: analysis of 61 cases. Sham RL; Ou CY; Cappuccio J; Braggins C; Dunnigan K; Phatak PD Blood Cells Mol Dis; 1997 Aug; 23(2):314-20. PubMed ID: 9410475 [TBL] [Abstract][Full Text] [Related]
23. Transferrin receptor-2 gene and non-C282Y homozygous patients with hemochromatosis. Aguilar-Martinez P; Esculié-Coste C; Bismuth M; Giansily-Blaizot M; Larrey D; Schved JF Blood Cells Mol Dis; 2001; 27(1):290-3. PubMed ID: 11358390 [TBL] [Abstract][Full Text] [Related]
24. HFE mutations, iron deficiency and overload in 10,500 blood donors. Jackson HA; Carter K; Darke C; Guttridge MG; Ravine D; Hutton RD; Napier JA; Worwood M Br J Haematol; 2001 Aug; 114(2):474-84. PubMed ID: 11529872 [TBL] [Abstract][Full Text] [Related]
25. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. Nelson JE; Brunt EM; Kowdley KV; Hepatology; 2012 Nov; 56(5):1730-40. PubMed ID: 22611049 [TBL] [Abstract][Full Text] [Related]
26. Hemochromatosis and iron-overload screening in a racially diverse population. Adams PC; Reboussin DM; Barton JC; McLaren CE; Eckfeldt JH; McLaren GD; Dawkins FW; Acton RT; Harris EL; Gordeuk VR; Leiendecker-Foster C; Speechley M; Snively BM; Holup JL; Thomson E; Sholinsky P; N Engl J Med; 2005 Apr; 352(17):1769-78. PubMed ID: 15858186 [TBL] [Abstract][Full Text] [Related]
28. Hereditary hemochromatosis in a Brazilian university hospital in São Paulo State (1990-2000). Martinelli AL; Filho R; Cruz S; Franco R; Tavella M; Secaf M; Ramalho L; Zucoloto S; Rodrigues S; Zago M Genet Mol Res; 2005 Mar; 4(1):31-8. PubMed ID: 15841433 [TBL] [Abstract][Full Text] [Related]
29. Differences in hepatic phenotype between hemochromatosis patients with HFE C282Y homozygosity and other HFE genotypes. Cheng R; Barton JC; Morrison ED; Phatak PD; Krawitt EL; Gordon SC; Kowdley KV J Clin Gastroenterol; 2009 Jul; 43(6):569-73. PubMed ID: 19359997 [TBL] [Abstract][Full Text] [Related]
31. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Walsh A; Dixon JL; Ramm GA; Hewett DG; Lincoln DJ; Anderson GJ; Subramaniam VN; Dodemaide J; Cavanaugh JA; Bassett ML; Powell LW Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1403-10. PubMed ID: 16979952 [TBL] [Abstract][Full Text] [Related]
32. Low frequency of HFE gene mutations in Croatian patients suspected of having hereditary hemochromatosis. Milić S; Ristić S; Starčević-Čizmarević N; Brajenović-Milić B; Crnić-Martinović M; Kapović M; Peterlin B; Štimac D Med Sci Monit; 2011 Oct; 17(10):CR552-6. PubMed ID: 21959608 [TBL] [Abstract][Full Text] [Related]
33. Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy. Cassanelli S; Pignatti E; Montosi G; Garuti C; Mariano M; Campioli D; Carbonieri A; Baldini E; Pietrangelo A J Hepatol; 2001 Apr; 34(4):523-8. PubMed ID: 11394651 [TBL] [Abstract][Full Text] [Related]
34. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Gurrin LC; Bertalli NA; Dalton GW; Osborne NJ; Constantine CC; McLaren CE; English DR; Gertig DM; Delatycki MB; Nicoll AJ; Southey MC; Hopper JL; Giles GG; Anderson GJ; Olynyk JK; Powell LW; Allen KJ; Hepatology; 2009 Jul; 50(1):94-101. PubMed ID: 19554541 [TBL] [Abstract][Full Text] [Related]
35. A genotypic study of 217 unrelated probands diagnosed as "genetic hemochromatosis" on "classical" phenotypic criteria. Brissot P; Moirand R; Jouanolle AM; Guyader D; Le Gall JY; Deugnier Y; David V J Hepatol; 1999 Apr; 30(4):588-93. PubMed ID: 10207799 [TBL] [Abstract][Full Text] [Related]
36. Mass spectrometry measurement of plasma hepcidin for the prediction of iron overload. Floreani A; Navaglia F; Rizzotto ER; Basso D; Chiaramonte M; Padoan A; Petridis I; Cazzagon N; Testa R; Marra M; Plebani M Clin Chem Lab Med; 2011 Feb; 49(2):197-206. PubMed ID: 21143008 [TBL] [Abstract][Full Text] [Related]
37. Population screening for hemochromatosis: a study in 5370 Spanish blood donors. Sánchez M; Villa M; Ingelmo M; Sanz C; Bruguera M; Ascaso C; Oliva R J Hepatol; 2003 Jun; 38(6):745-50. PubMed ID: 12763366 [TBL] [Abstract][Full Text] [Related]
38. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Kemna EH; Tjalsma H; Podust VN; Swinkels DW Clin Chem; 2007 Apr; 53(4):620-8. PubMed ID: 17272487 [TBL] [Abstract][Full Text] [Related]
39. HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS Study participants. Barton JC; Lafreniere SA; Leiendecker-Foster C; Li H; Acton RT; Press RD; Eckfeldt JH Am J Hematol; 2009 Nov; 84(11):710-4. PubMed ID: 19787796 [TBL] [Abstract][Full Text] [Related]
40. Relation between HFE mutations and mild iron-overload expression. Mura C; Le Gac G; Raguénes O; Mercier AY; Le Guen A; Férec C Mol Genet Metab; 2000 Apr; 69(4):295-301. PubMed ID: 10870847 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]